Missing data
Written by: | Posted on: | Category:

When it comes to assessing the impact of how well patients (and arguably centres) in a randomised clinical trial follow the protocol, the standard method for some decades has been via the identification of the ‘Per Protocol’ set. This ICH-driven subset of ITT patients essentially requires the review of blinded patient data at the end of the trial. ...

Written by: | Posted on: | Category:

NICE are currently undergoing what appears to be quite a wide re-evaluation of their HTA process. As part of this process, they have recently released a white paper for comment, entitled “The NICE methods of health technology evaluation: the case for change”.

I've picked out some (mostly statistical) highlights:

  1. End-of-life patient ...
Written by: | Posted on: | Category:

ISPOR’s Value and Outcomes Spotlight recent Sep/Oct 2020 issue contained an interesting Q&A article with Jennifer Graff (VP, Comparative-Effectiveness Research, National Pharmaceutical Council). Overall, it was interesting, high-level stuff - which raised a few Qs in my head. Some extracts from the article:

"Researchers have estimated ...

Written by: | Posted on: | Category:

Another FDA guideline on COVID-19 has just been released and, given the pressing nature of the current pandemic, comes into immediate effect: https://www.fda.gov/media/142749/download

I’ve picked out a couple of sections from the guidance, along with my thoughts on each…

“...issuance ...

By clicking "Accept," you agree to the use of Numerus and third party cookies and other similar technologies to enhance your browsing experience, analyse, and measure your engagement with our content.